LakeShore Biopharma Co., Ltd (LSB)
NASDAQ: LSB · IEX Real-Time Price · USD
0.490
-0.010 (-2.02%)
At close: Jul 19, 2024, 4:00 PM
0.410
-0.080 (-16.31%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer.
The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024.
LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
LakeShore Biopharma Co., Ltd
| Country | China |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 773 |
| CEO | Dave Chenn |
Contact Details
Address: Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park Daxing District, Beijing, F4 102629 China | |
| Phone | 17327133678 |
| Website | ysbiopharm.com |
Stock Details
| Ticker Symbol | LSB |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | CNY |
| CIK Code | 0001946399 |
| ISIN Number | KYG9845F1090 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 5, 2024 | 6-K | Report of foreign issuer |
| Jun 18, 2024 | 6-K | Report of foreign issuer |
| Jun 10, 2024 | 6-K | Report of foreign issuer |
| May 24, 2024 | 6-K | Report of foreign issuer |
| May 21, 2024 | 6-K | Report of foreign issuer |
| May 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 8, 2024 | 424B3 | Prospectus |
| May 7, 2024 | 6-K | Report of foreign issuer |
| Apr 29, 2024 | 6-K | Report of foreign issuer |
| Apr 19, 2024 | 6-K | Report of foreign issuer |